ORCHIDPHAR

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated March 30, 2010 titled "Orchid completes Business Transfer transaction with Hospira, Inc". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchidchemicals_pr_31032010.ZIP target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Board at its meeting held on December 15, 2009, has approved the sale and transfer of its generic injectables pharmaceuticals business to Hospira, Inc., USA. The acquisition by Hospira includes Orchid's beta-lactam antibiotics manufacturing complex (comprising cephalosporin, penicillin and carbapenem facilities) and pharmaceutical research and development (R&D) facility at Irungattukottai (Chennai), India as well as its generic injectable product portfolio and pipeline. Hospira would have access to the talented bases of

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated October 30, 2009 titled "Orchid registers revenue of Rs 314 crore during Q2 FY10". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_30102009.ZIP target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated October 19, 2009, titled "Orchid awarded the Corporate Social Responsibility Award 2008-09 by Government of Tamilnadu". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_20102009.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has submitted to the Exchange a copy of the press release issued by the company, regarding an updated note on Piperacillin Tazobactam product in the US. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_pr_25092009.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has submitted to the Exchange a press release regarding an Information note on Piperacillin Tazobactam. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_PR_24092009.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the press release dated July 31, 2009 titled "Orchid registers turnover of Rs 309 crore during Q1 FY10". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_31072009.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the press release dated July 03, 2009 titled "Orchid receives US FDA approval for Amlodipine Besylate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_PR_03072009.ZIP target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the press release dated June 29, 2009, titled " Orchid registers a turnover of Rs. 1211 crore during FY09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_pressrel_29062009.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated April 09, 2009, titled "Orchid's facility conferred global recognition". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidChem_PR_09042009.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated January 28, 2009, titled "Orchid registers turnover of Rs.310 crore during Q3 FY09 Maintains operational profitability (PBT) at Rs.28 crore; Earnings for the quarter ended December 31, 2008 (Q3 FY09)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_PR_28012009.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated January 16, 2009, titled "Orchid receives US FDA approval for Levetiracetam Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_16012009.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the press release dated October 30, 2008, titled "Orchid's revenue during Q2FY09 rises by 18.7% to Rs. 348.45 crore; Achieves Salient progress in the Generics and R & D Verticals". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_30102008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated October 16, 2008, titled "Orchid receives US FDA approvals for three Cefuroxime Inj. ANDAs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_16102008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated September 29, 2008, titled "Orchid & Merck & Co., Inc. collaborate to develop novel anti-infective drugs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_29092008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the press release dated August 13, 2008, titled "Orchid to develop Novel Anticoagulant Drug Candidate from Merck". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_14082008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the press release dated August 04, 2008, titled "Orchid receives EU approvals for Piperacillin Tazobactam injection". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_04082008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated July 30, 2008, titled "Orchid's Q1 FY09 income grows 30%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_30072008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated June 24, 2008, titled, "Orchid receives Canadian approval for Piperacillin Tazobactam injection". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_24062008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated May 29, 2008, titled "Orchid's FY08 turnover rises by 36% to Rs.1239 crore; Net profit records a growth of 91%; Board recommends dividend of 30%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_29052008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the Press Release dated March 18, 2008 titled " Orchid Chemicals clarifies on market fall of its shares". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_PR_18032008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated February 20, 2008, titled "Orchid receives US FDA approval for Cefuroxime Axetil ANDA ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_20022008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated February 14, 2008, titled "Orchid receives USFDA nod for Granisetron generic formulation First Indian company to be approved for this non-antibiotic product". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidChem_PR_14022008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated February 08, 2008, titled "Orchid ropes in Dr Gopalan to head its Drug Discovery initiatives; To head Orchid Research Labs as CSO & Director". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_08022008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated January 17, 2008, titled "Orchid's Q3 FY08 revenue up by 39% to Rs 333 crore; Net Profit rises by 91% to Rs. 54 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_17012008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated January 11, 2008, titled "Orchid's formulation facilities receive MCC (South Africa) nod Cephalosporin & Penicillin Injectable facilities approved". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_11012008.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated November 16, 2007, titled "Orchid receives US FDA approval for Cefpodoxime Proxetil ANDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_16112007.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated October 18, 2007, titled "Orchid's Q2 FY08 revenue higher by 20% at Rs 295 crore ; Net profit jumps 115% to Rs 63 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_PR_181007.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated July 20, 2007, titled "Orchid receives US FDA approval for its Cefdinir ANDAs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_20072007.zip target=NEW> For more details click here.</a>

Orchid Chemicals Ltd has informed the Exchange regarding a press release dated July 19, 2007, titled "Orchid Q1 FY 2007-08 net profit surges by 252% to Rs 51 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_19072007.zip target=NEW> For more details click here.</a>

Orchid Chemicals Ltd has informed the Exchange that: "Orchid has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for CEfepime injection. The product is available in three dosage strength 500 mg/vial, 1 gram/vial, and 2 grams/vial". A copy of the press release dated June 21, 2007, titled "Orchid receives US FDA approval for its Cefepime ANDA" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidChemPharma_PR_21062007.

Orchid Chemicals Ltd has informed the Exchange regarding a press release dated June 15, 2007, titled "Orchid forays into the non-antibiotic generic formulations segment". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidChemnPharma_PR_150607.zip target=NEW> For more details click here.</a>

Orchid Chemicals Ltd has informed the Exchange regarding a press release dated May 03, 2007, titled "Orchid's turnover rises to Rs.934 crore during FY 2006-07- Net profit increases to Rs 97 crore". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_PR_03052007.zip target=NEW> For more details click here.</a>

Orchid Chemicals Ltd has informed the Exchange that: "Orchid's wholly-owned Drug Discovery subsidiary in Chennai, Orchid Research Laboratories Ltd (ORLL) has been conferred the Frost & Sullivan Award for Partner of Choice in Contract Research - Collaborative Drug Discovery". A copy of the press release issued by the Company dated April 30, 2007, titled "Orchid's drug discovery subsidiary (Orchid Research Labs) awarded Partner of Choice award by Frost & Sullivan" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (

Orchid Chemicals Ltd has informed the Exchange that "Orchid has received the approval from the Canadian TPD (Therapeutic Product Directorate) for 2 of its ANDS (Abbreviated New Drug Submission) applications. These approvals correspond to two generic formulations, Cefoxitin and Ceftriaxone". Further the Company has submitted a copy of press release dated April 03, 2007, titled "Orchid to foray into the Canadian generic formulations market". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extra

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated February 25, 2007, titled "Orchid's Zero coupon FCCB issue to retire foreign currency debt and support other business purposes". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_press1_260207.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has entered into a licensing and distribution agreement with the international generic pharmaceuticals company Actavis, Iceland for marketing 9 of Orchid's cephalosporin generic formulations in Europe. A copy of press release in this regard dated February 01, 2007, titled �Orchid in a new licensing and distribution alliance with Actavis to market cephalosporin formulations in Europe" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated January 19,2007, titled "Orchid registers turnover of Rs 239 crore during Q3 FY 2006-07; Net profit stands at Rs 28 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_19012007.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has signed a contract with Biovitrum to undertake medicinal chemistry work to support certain drug discovery activities of Biovitrum AB (publ). A press release dated October 30,2006, titled "Orchid signs deal with Biovitrum in drug discovery field" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidCh_PR_30102006.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated October 19,2006, titled "Orchid's Q2 FY07 net profit rises to Rs 29 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidChem_PR_19102006.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefadroxil 500 mg Capsules and 1 g Tablets. The Company has also submitted a copy of press release, dated September 22, 2006, titled "Orchid receives USFDA approvals for Cefadroxil ANDAs". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_2

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the approvals from the UK regulator, Medicines and Healthcare products Regulatory Agency (MHRA) for sterile cephalosporin Finished Dosage Form (formulations) and Active Pharmaceutical Ingredients (APIs) facilities located near Chennai in Irungattukottai and Alathur respectively. The Company has also submitted a copy of press release, dated September 21, 2006, titled "Orchid's Formulation and API facilities approved by the UK MHRA." The details of the press release shall be available on the NSE website (ht

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefotaxime for injection in various dosage forms. A copy of the press release dated August 16, 2006, titled " Orchid receives USFDA approvals for Cefotaxime Injection ANDAs -Mature genertic product with limited competition "shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid and Bexel Pharmaceuticals Inc. have reached understanding by which Orchid would extend its ownership in Bexel from the current 74% to 100%. Further, a copy of the press release dated July 31,2006, titled "Orchid undertakes structural consolidation of global discovery research" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated July 12,2006, titled "Orchid receives USFDA approval for Cephalexin oral suspension ANDA". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has entered into a long-term Master Research & Development agreement with Pfizer International, LLC for providing research and development services to Pfizer's Animal Health business. A copy of the Press Release issued by the company on February 16, 2006 regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefoxitin for injection, 1gm/vial and 2gm/vial. A copy of the Press Release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has issued a press release dated January 19, 2006, titled "Orchid registers turnover of Rs.238 crore during Q3 FY 2005-06 - Net profit jumps by 402% to Rs.29 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefprozil Tablets USP 250mg and 500mg. The approval of USFDA for the ANDA would enable the Company to launch the product in the US. A copy of the Press Release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated December 02, 2005 titled, "His Excellency The President of India visits Orchid's state-of-the-art formulations manufacturing complex; Addresses scientists and staff on drug discovery opportunity". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).